Pralsetinib Disease Interactions
There are 4 disease interactions with pralsetinib.
Pralsetinib (applies to pralsetinib) hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Pralsetinib has not been studied in patients with moderate or severe hepatic impairment. Additionally, clinical trials reported hepatotoxicity in some patients receiving treatment. Caution and close monitoring is advised if administering in patients with hepatic impairment.
Pralsetinib (applies to pralsetinib) hypertension
Moderate Potential Hazard, Moderate plausibility.
Hypertension has been reported in patients in treatment with pralsetinib. This drug should not be initiated in patients with uncontrolled hypertension. Caution and close monitoring is advised.
Pralsetinib (applies to pralsetinib) QT prolongation
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Long QT Syndrome, Hypokalemia, Magnesium Imbalance, Hypocalcemia
QT prolongation was reported in clinical trials in patients that received pralsetinib. Use with caution in patients with history of arrhythmias, QT prolongation or taking medications that can prolong the QT interval (e.g., strong CYP450 3A4 inhibitors). Monitor QT interval and serum electrolytes before initiation and regularly during treatment. Hypokalemia, hypomagnesemia, and hypocalcemia should be corrected prior and during treatment.
Pralsetinib (applies to pralsetinib) renal dysfunction
Moderate Potential Hazard, Moderate plausibility.
Pralsetinib has not been studied in patients with severe renal impairment or end-stage renal disease. Caution is advised if administering in these patients.
Switch to professional interaction data
Pralsetinib drug interactions
There are 714 drug interactions with pralsetinib.
Pralsetinib alcohol/food interactions
There are 2 alcohol/food interactions with pralsetinib.
Report options
More about pralsetinib
- pralsetinib consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Rybrevant
Rybrevant is used to treat certain types of non-small cell lung cancer (NSCLC) in adults. It is ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Avastin
Avastin is used to brain tumors and cancers of the kidney, colon, rectum, or lung. Learn about side ...
Cisplatin
Cisplatin systemic is used for anal cancer, bladder cancer, blood cell transplantation, bone marrow ...
Pembrolizumab
Pembrolizumab (Keytruda) is a monoclonal antibody cancer medicine used to treat
Methotrexate
Methotrexate is used to treat certain types of cancer of the breast, skin, head and neck, or lung ...
Armour Thyroid
Armour Thyroid is used for hashimoto's disease, hypothyroidism, after thyroid removal, thyroid ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
